By Tom Winnifrith & Steve Moore | Thursday 24 November 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O'Hara.
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Time left: 20:34:50